NOVATO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and IGAN Biosciences announced today that they have initiated a program to develop an IgA protease for treating IgA nephropathy. IgA proteases have been shown to cleave IgA complexes, the deposition of which causes IgA nephropathy, an orphan kidney disorder with few treatment alternatives. BioMarin has executed a research and option agreement with IGAN Biosciences for intellectual property covering IgA proteases for treating IgA nephropathy.
"IgA proteases have the potential to reverse or prevent progression of IgA Nephropathy," said Dr. Andrew Plaut, discoverer of IgA proteases, Professor of Medicine at Tufts University School of Medicine, and Chairman of IGAN Biosciences. "Current treatments are not very effective, and nothing on the horizon looks very promising. BioMarin has a strong track record of aggressively developing disease modifying therapeutics for rare disorders, and I am very pleased that they have made a commitment to further these important efforts."
"Dr. Plaut's laboratory has performed pioneering work in the field of IgA proteases," Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin commented. "These proteases are exceptionally specific for IgA and show promise for treating the underlying pathophysiology of IgA nephropathy. In collaboration with IGAN and the Tufts-New England Medical Center, we look forward to testing these proteases in animal models of IgA nephropathy, and if successful, developing an efficacious therapeutic for the disorder."
"We are pleased to add this program to our growing product development
pipeline. The IgA nephropathy indication aligns well with our development
and commercial competencies as it is a protein therapeutic for treating a
well- defined and relatively large orphan disorder treated by renal
specialists," said Jean-Jacques Bienaime, Chief Executive Officer of
BioMarin. "Well val
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2007 PR Newswire.
All rights reserved